Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Downgrades ResMed to Neutral

JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.

byBenzinga Newsdesk

August 12, 2022

1 minute read

JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.

News

Musk Fancies Himself A ‘Free Speech Absolutist,’ Pitches Futurism In Magazine Run By China Censor

By Shivdeep Dhaliwal

Today, 7:31 PM

Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk has penned a piece for the mouthpiece of the Cyberspace Administration of China (CAC), an agency that censors the internet for Beijing.

TSLA

Anixa Biosciences Says COVID-19 Compounds Potentially Effective Against Omicron Variant

By Vandana Singh

Today, 7:31 PM

Anixa Biosciences Inc (NASDAQ: ANIX)

ANIX

AstraZeneca, Merck Report LYNPARZA Plus Abiraterone Reduced Risk Of Disease Progression By 34% vs Standard Of Care In First-Line Metastatic Castration-Resistance Prostate Cancer

By Benzinga Newsdesk

Today, 7:31 PM

Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone PROpel Phase III trial results show clinically meaningful benefit in patients

AZN

Donaldson Q1 EPS $0.61 Beats $0.55 Estimate, Sales $760.90M Beat $745.38M Estimate

By Bill Haddad

Today, 7:31 PM

Donaldson (NYSE:DCI) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.55 by 10.91 percent. This is a 27.08 percent increase over earnings of $0.48 per share from the same

DCI

JP Morgan Downgrades ResMed to Neutral

Related Posts

Musk Fancies Himself A ‘Free Speech Absolutist,’ Pitches Futurism In Magazine Run By China Censor

Anixa Biosciences Says COVID-19 Compounds Potentially Effective Against Omicron Variant

AstraZeneca, Merck Report LYNPARZA Plus Abiraterone Reduced Risk Of Disease Progression By 34% vs Standard Of Care In First-Line Metastatic Castration-Resistance Prostate Cancer

Donaldson Q1 EPS $0.61 Beats $0.55 Estimate, Sales $760.90M Beat $745.38M Estimate